Immunovia publishes prospectus regarding preferential

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES,
AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR
WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE
WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

Immunovia publishes prospectus regarding preferential rights issue

Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in
connection with the Company’s preferential rights issue (the “Rights Issue”).

Publication of prospectus
Immunovia’s prospectus, prepared in connection with the Rights Issue, has today
been approved and registered by the Swedish Financial Supervisory Authority. The
prospectus has today been published and is also available on the company’s web
page http://immunovia.com/investors/ and the Company’s head office.
Time table for the Rights Issue

26 September 2016 Last day of
trading in the shares including subscription rights.

27 September 2016 First day of
trading in the shares without the right to participate in the Rights Issue.

28 September 2016 Record date
for participation in the Rights Issue. Registered shareholders included in the
share register held by Euroclear Sweden AB will receive subscription rights
carrying the right to participate in the Rights Issue.

3 October ‑ 17 October 2016 Subscription period.

3 October ‑ 13 October 2016 Trading in
subscription rights.

3 October - 26 October 2016 Trading in paid
subscribed shares (sw. BTA).

20 October 2016 The outcome of
the Rights Issue is announced.

Beginning of November The Rights Issue is
completed and registered.

Advisors
Vator Securities AB is financial advisor to Immunovia and Baker & McKenzie
Advokatbyrå KB is legal advisor to Vator Securities AB and Immunovia in
connection with the Rights Issue.

For further information, contact:
Mats Grahn, CEO Immunovia AB
Phone: +46 (0)70-532 02 30
E-mail: mats.grahn@immunovia.com

This information is information that Immunovia AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was submitted
for publication, through the agency of the contact person set out above, at
13.30 CET on 26 September 2016.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of
Immunotechnology at Lund University and CREATE Health, the Center for
Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to
decipher the wealth of information in blood and translate it into clinically
useful tools to diagnose complex diseases such as cancer, earlier and more
accurately than previously possible. Immunovia´s core technology platform,
IMMray™, is based on antibody biomarker microarray analysis. The company is now
performing clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early diagnosis of
pancreatic cancer. In the beginning of 2016, the company started a program
focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The
first test from this program, IMMray™ SLE-d, is a biomarker signature derived
for differential diagnosis of lupus, now undergoing evaluation and validation.
(Source: www.immunovia.com)

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and
Wildeco is the company’s Certified Adviser. For more information, please visit
www.immunovia.com.

IMPORTANT INFORMATION

This press release is not an offer or solicitation to acquire shares in
Immunovia. A prospectus relating to the Rights Issue referred to in this press
release will be filed with the Swedish Financial Supervisory Authority. After
approval and registration of the prospectus by the Swedish Financial Supervisory
Authority, the prospectus will be published and made available on i.e.
Immunovia’s website.

This press release does not constitute or form part of an offer or solicitation
to purchase or subscribe for securities in the United States. The securities
referred to herein may not be sold in the United States absent registration or
an exemption from registration under the US Securities Act of 1933, as amended.
Immunovia does not intend to register any portion of the offering of the
securities in the United States or to conduct a public offering of the
securities in the United States. The information in this press release may not
be announced, published or distributed, directly or indirectly, to the United
States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong
Kong or in any other jurisdiction where the announcement, publication or
distribution of the information would not comply with applicable laws and
regulations.

###

Immunovia publishes prospectus regarding preferential rights issue

Attachments